11. Sifuvirtide, A Novel HIV-1 Fusion Inhibitor

  1. Prof. Dr. Miguel Castanho and
  2. Prof. Dr. Nuno C. Santos
  1. Xiaobin Zhang1,
  2. Hao Wu2 and
  3. Fengshan Wang3

Published Online: 17 OCT 2011

DOI: 10.1002/9783527636730.ch11

Peptide Drug Discovery and Development: Translational Research in Academia and Industry

Peptide Drug Discovery and Development: Translational Research in Academia and Industry

How to Cite

Zhang, X., Wu, H. and Wang, F. (2011) Sifuvirtide, A Novel HIV-1 Fusion Inhibitor, in Peptide Drug Discovery and Development: Translational Research in Academia and Industry (eds M. Castanho and N. C. Santos), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527636730.ch11

Editor Information

  1. University of Lisbon, Institute of Biochemistry, Av. Egas Moniz, 1649-028 Lisboa, Portugal

Author Information

  1. 1

    FusoGen Pharmaceuticals, Inc., Ping'an Building B19-A, 59 Machang Road, Hexi District, 300203 Tianjin, P. R. China

  2. 2

    Beijing You'an Hospital, Capital Medical University, Department of Infectious Diseases, 100069 Beijing, P. R. China

  3. 3

    Shandong University, Institute of Biochemical and Biotechnological Drug, School of Pharmaceutical Sciences, Jinan, 250012 Shandong, P. R. China

Publication History

  1. Published Online: 17 OCT 2011
  2. Published Print: 5 OCT 2011

ISBN Information

Print ISBN: 9783527328918

Online ISBN: 9783527636730

SEARCH

Keywords:

  • HIV-1;
  • sifuvirtide;
  • fusion inhibitor;
  • biomembrane selectivity;
  • stratification;
  • monotherapy

Summary

This chapter contains sections titled:

  • Ideal Drug Target HIV-1 gp41

  • Structure-Based Drug Design of Sifuvirtide

  • High Potency of Sifuvirtide

  • Limited Drug Resistance

  • Enhancement of the Efficiency of Sifuvirtide by Biomembrane Selectivity

  • Pharmacokinetics of Sifuvirtide with Long Half-Life

  • Stratification of Monotherapy

  • 20 mg Sifuvirtide Once Daily vs. 100 mg T20 Twice Daily

  • Conclusions and Discussion